DE60129069D1 - Hepatitis B Virus Vektoren für Gentherapie - Google Patents

Hepatitis B Virus Vektoren für Gentherapie

Info

Publication number
DE60129069D1
DE60129069D1 DE60129069T DE60129069T DE60129069D1 DE 60129069 D1 DE60129069 D1 DE 60129069D1 DE 60129069 T DE60129069 T DE 60129069T DE 60129069 T DE60129069 T DE 60129069T DE 60129069 D1 DE60129069 D1 DE 60129069D1
Authority
DE
Germany
Prior art keywords
hepatitis
gene therapy
virus vectors
vivo
deliver therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60129069T
Other languages
English (en)
Inventor
Wang-Shick Ryu
Jehan Lee
Jong Keun Jeong
Woo Young Cho
Gye Soon Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2001-0019645A external-priority patent/KR100452718B1/ko
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60129069D1 publication Critical patent/DE60129069D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2730/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60129069T 2000-04-20 2001-04-20 Hepatitis B Virus Vektoren für Gentherapie Expired - Lifetime DE60129069D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20000021070 2000-04-20
KR10-2001-0019645A KR100452718B1 (ko) 2000-04-20 2001-04-12 유전자 치료용 재조합 ｂ형 간염 바이러스 플라스미드 벡터

Publications (1)

Publication Number Publication Date
DE60129069D1 true DE60129069D1 (de) 2007-08-09

Family

ID=26637882

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60129069T Expired - Lifetime DE60129069D1 (de) 2000-04-20 2001-04-20 Hepatitis B Virus Vektoren für Gentherapie

Country Status (5)

Country Link
US (1) US7001760B2 (de)
EP (1) EP1149917B1 (de)
JP (1) JP3621355B2 (de)
AT (1) ATE365807T1 (de)
DE (1) DE60129069D1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US7015317B2 (en) * 2002-05-02 2006-03-21 Abbott Laboratories Polynucleotides for the detection and quantification of hepatitis B virus nucleic acids
KR101012595B1 (ko) * 2005-03-09 2011-02-07 재단법인 목암생명공학연구소 작은 간섭 ｒｎａ 및 이를 포함하는 ｂ형 간염 바이러스 치료용 약학 조성물
EP2426142A3 (de) 2006-10-16 2012-06-13 Genelux Corporation Modifizierte Impfstoffvirusstämme zur Verwendung in einem Diagnose- und Therapieverfahren
US8071561B2 (en) * 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
CA2699465C (en) * 2007-09-14 2017-11-28 Institut Pasteur Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
US10363323B2 (en) 2011-02-10 2019-07-30 Ruprecht-Karls-Universitat Heidelberg Hydrophobic modified peptides for liver specific diagnosis
EP2673004B1 (de) 2011-02-10 2018-01-24 Ruprecht-Karls-Universität Heidelberg Hydrophob modifizierte peptide und ihre verwendung für leberspezifisches targeting
WO2015057919A1 (en) * 2013-10-18 2015-04-23 The Johns Hopkins University Transgenic hepatitis b virus (hbv): a new model of hbv infection identifies uqcr10 as a viral replication factor
EP3189850A1 (de) 2015-12-16 2017-07-12 Ruprecht-Karls-Universität Heidelberg Auf die leber gerichtete cyclische pres-peptide von hbv
CA3149041A1 (en) * 2019-08-29 2021-03-04 Serhat GUMRUKCU Compositions and methods for treating viral infections
CN111575316A (zh) * 2020-05-19 2020-08-25 东莞市松山湖中心医院(东莞市石龙人民医院、东莞市第三人民医院、东莞市心血管病研究所) hKLK1重组质粒、高表达hKLK1的慢病毒颗粒及其构建方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN151589B (de) * 1978-12-22 1983-05-28 Biogen Nv
EP0180012A1 (de) * 1984-10-27 1986-05-07 Wolfram H. Prof. Dr. Gerlich Immunogene Polypeptidsequenz des Hepatitis B-Virus
KR970007153B1 (ko) * 1987-06-22 1997-05-03 메데바 홀딩스 비브이 B형 간염 표면 항원 백신
FR2711670B1 (fr) * 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US5744326A (en) * 1996-03-11 1998-04-28 The Immune Response Corporation Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
GB9707221D0 (en) * 1997-04-09 1997-05-28 Univ Glasgow Hepatitis B virus mutations

Also Published As

Publication number Publication date
US20010049145A1 (en) 2001-12-06
ATE365807T1 (de) 2007-07-15
US7001760B2 (en) 2006-02-21
EP1149917A3 (de) 2001-11-14
JP3621355B2 (ja) 2005-02-16
EP1149917B1 (de) 2007-06-27
JP2002320480A (ja) 2002-11-05
EP1149917A2 (de) 2001-10-31

Similar Documents

Publication Publication Date Title
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
ATE365807T1 (de) Hepatitis b virus vektoren für gentherapie
MX2008001865A (es) Proteinas de fusion de albumina.
TR201906106T4 (tr) Amiyotrofik lateral skleroz ve diğer omurilik hastalıkları için gen tedavisi.
DK1124846T3 (da) Nukleotid- og proteinsekvenser af Nogo-gener og derpå baserede fremgangsmåder
CY1108478T1 (el) Ιος της ομαδας pox με στοχοθετημενη ειδικοτητα μολυνσης
DK1204739T3 (da) Forögelse af ekspression af en enkeltstrenget, heterolog nukleotidsekvens fra rekombinante, virale vektorer ved en sådan udformning af sekvensen at den danner intrastrengbasepar
ATE531808T1 (de) Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna
MX2020010994A (es) Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial.
ATE444361T1 (de) Il-17 und il-17r homologe polypeptide und deren therapeutische verwendungen
DK1677833T3 (da) Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom
ATE335086T1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
ATE438727T1 (de) Optimierung von transgenexpression in säugetierzellen
MX2021006253A (es) Terapias génicas para enfermedad neurodegenerativa.
DE60331758D1 (de) Neue vollständige genomische rna des japanenzephalitis-virus, infektiöse jev cdna daraus und deren verwendung
DE69930123D1 (de) Zielgerichtete integration in chromosomen mittels retroviraler vektoren
CY1108552T1 (el) Θεραπευτικη αντιμετωπιση της μη αλκοολικης στεατοηπατιτιδας (nash)
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
ATE338826T1 (de) Rekombinante virale vektoren zur tetracyclinregulierbaren genexpression
ITMI20030860A1 (it) Metodo per l'inibizione selettiva del gene n-myc
DE60002603D1 (de) Phosphor-enthaltende dendrimere als transfektionsagente
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen
WO2005094415A3 (en) Recombinant vectors and methods for inducing an immune response
DE60031539D1 (de) Mutiertes nurr1 gen

Legal Events

Date Code Title Description
8332 No legal effect for de